GB202101125D0 - Antibodies and uses thereof - Google Patents
Antibodies and uses thereofInfo
- Publication number
- GB202101125D0 GB202101125D0 GBGB2101125.9A GB202101125A GB202101125D0 GB 202101125 D0 GB202101125 D0 GB 202101125D0 GB 202101125 A GB202101125 A GB 202101125A GB 202101125 D0 GB202101125 D0 GB 202101125D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/089—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2101125.9A GB202101125D0 (en) | 2021-01-27 | 2021-01-27 | Antibodies and uses thereof |
PCT/EP2022/051959 WO2022162097A2 (en) | 2021-01-27 | 2022-01-27 | Antibodies and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2101125.9A GB202101125D0 (en) | 2021-01-27 | 2021-01-27 | Antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
GB202101125D0 true GB202101125D0 (en) | 2021-03-10 |
Family
ID=74858954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB2101125.9A Ceased GB202101125D0 (en) | 2021-01-27 | 2021-01-27 | Antibodies and uses thereof |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB202101125D0 (en) |
WO (1) | WO2022162097A2 (en) |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
CA2109528A1 (en) | 1991-05-01 | 1992-11-02 | Gregory A. Prince | A method for treating infectious respiratory diseases |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
ATE508733T1 (en) | 1996-03-04 | 2011-05-15 | Penn State Res Found | MATERIALS AND METHODS FOR INCREASE CELLULAR INTERNALIZATION |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
PT954282E (en) | 1997-01-16 | 2005-06-30 | Massachusetts Inst Technology | PREPARATION OF PARTICLES FOR INHALATION |
AU747231B2 (en) | 1998-06-24 | 2002-05-09 | Alkermes, Inc. | Large porous particles emitted from an inhaler |
AT503889B1 (en) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | MULTIVALENT IMMUNE LOBULINE |
US20160289303A1 (en) | 2013-11-15 | 2016-10-06 | President And Fellows Of Harvard College | Methods and compositions for the treatment of hcmv |
US20180327482A1 (en) * | 2013-11-15 | 2018-11-15 | President And Fellows Of Harvard College | Methods and compositions for the treatment of hcmv |
RU2769133C2 (en) | 2013-12-30 | 2022-03-28 | Эпимаб Биотерапьютикс Инк. | Immunoglobulin with tandem arrangement of fab fragments and application thereof |
-
2021
- 2021-01-27 GB GBGB2101125.9A patent/GB202101125D0/en not_active Ceased
-
2022
- 2022-01-27 WO PCT/EP2022/051959 patent/WO2022162097A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2022162097A3 (en) | 2022-09-22 |
WO2022162097A2 (en) | 2022-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276950A (en) | Anti-cd73 antibodies and uses thereof | |
IL289585A (en) | Dll3-targeting antibodies and uses thereof | |
IL275826A (en) | Anti-mct1 antibodies and uses thereof | |
SG11202112112UA (en) | Anti-galectin-9 antibodies and uses thereof | |
GB202017058D0 (en) | Antibodies and uses thereof | |
IL291027A (en) | Anti-steap1 antibodies and uses thereof | |
IL289656A (en) | Anti-tigit antibodies and application thereof | |
IL310938A (en) | Anti-ccr8 antibodies and uses thereof | |
IL287690A (en) | Anti-hvem antibodies and use thereof | |
IL277330A (en) | Anti-il-27 antibodies and uses thereof | |
IL277075A (en) | Anti-phf-tau antibodies and uses thereof | |
IL276548A (en) | Bcma-binding antibodies and uses thereof | |
EP4095157A4 (en) | Anti-angptl3 antibody and use thereof | |
IL291550A (en) | Anti-il-27 antibodies and uses thereof | |
IL291546A (en) | Anti-kir3dl3 antibodies and uses thereof | |
IL308808A (en) | Anti-ccr8 antibodies and uses thereof | |
IL307267A (en) | Anti-cd122 antibodies and uses thereof | |
IL310514A (en) | B7h6 antibody and use thereof | |
EP4169950A4 (en) | Anti-lilrb1 antibody and uses thereof | |
IL291280A (en) | Anti-cd371 antibodies and uses thereof | |
IL286803A (en) | Anti-tauc3 antibodies and uses thereof | |
EP4234580A4 (en) | Nkg2a-targeting antibody and use thereof | |
EP4079758A4 (en) | Semg2 antibody and use thereof | |
IL279790A (en) | Anti-l1cam antibodies and uses thereof | |
GB201902590D0 (en) | Antibodies and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |